abstract: BACKGROUND AND AIM: To report on the prevalence of @entity2 ( @entity2 ) related @entity6 and @entity1 in northwestern Greece. @entity0 AND METHODS: Single referral center retrospective study. The policy among all gastroenterologists of the area regarding medical treatment, @entity0 follow up and bowel surveillance strategies including risk factors is the same. RESULTS: We analyzed 1494 colonoscopies from 696 consecutive @entity2 @entity0 (494 UC). The follow up time [median, IQR] was 16 [8-23] years and the age at diagnosis was 28 [21-49] years. The number of @entity0 years at risk was 16.219. Disease location for UC was: pancolitis 761 (59%), @entity7 455 (35%), and @entity9 69 (6%). Disease location for @entity4 was: colitis 142 (66%), @entity10 45 (22%) and @entity3 21 (10%). Disease activity was in remission in 1240 (83%) of them. In total, 498 (72%) @entity0 were on @entity8 , 169(24%) on immunosuppression and 29 (4%) on biologicals. Biopsies were taken randomly in 1429 (96%) endoscopies and were targeted in 65 (4%) of them. We recorded 69 (9.4%) cases with @entity5 and 10 (1.4%) cases with @entity1 (9 in UC). No difference was found for @entity5 and @entity1 in @entity0 who followed up for 10-20 years or for more than 20 years. CONCLUSIONS: The prevalence of @entity5 and @entity1 is increased in UC compared to @entity4 but the prevalence of high-grade @entity5 is comparatively low. @entity1 prevalence is increasing after the first decade and then practically remains stable.

title: Prevalence of @entity2 related XXXX and @entity1 in 1500 colonoscopies from a referral center in northwestern Greece.

answer: @entity5


abstract: BACKGROUND AND AIM: To report on the prevalence of @entity2 ( @entity2 ) related @entity6 and @entity1 in northwestern Greece. @entity0 AND METHODS: Single referral center retrospective study. The policy among all gastroenterologists of the area regarding medical treatment, @entity0 follow up and bowel surveillance strategies including risk factors is the same. RESULTS: We analyzed 1494 colonoscopies from 696 consecutive @entity2 @entity0 (494 UC). The follow up time [median, IQR] was 16 [8-23] years and the age at diagnosis was 28 [21-49] years. The number of @entity0 years at risk was 16.219. Disease location for UC was: pancolitis 761 (59%), @entity7 455 (35%), and @entity9 69 (6%). Disease location for @entity4 was: colitis 142 (66%), @entity10 45 (22%) and @entity3 21 (10%). Disease activity was in remission in 1240 (83%) of them. In total, 498 (72%) @entity0 were on @entity8 , 169(24%) on immunosuppression and 29 (4%) on biologicals. Biopsies were taken randomly in 1429 (96%) endoscopies and were targeted in 65 (4%) of them. We recorded 69 (9.4%) cases with @entity5 and 10 (1.4%) cases with @entity1 (9 in UC). No difference was found for @entity5 and @entity1 in @entity0 who followed up for 10-20 years or for more than 20 years. CONCLUSIONS: The prevalence of @entity5 and @entity1 is increased in UC compared to @entity4 but the prevalence of high-grade @entity5 is comparatively low. @entity1 prevalence is increasing after the first decade and then practically remains stable.

title: Prevalence of XXXX related @entity5 and @entity1 in 1500 colonoscopies from a referral center in northwestern Greece.

answer: @entity2


abstract: BACKGROUND AND AIM: To report on the prevalence of @entity2 ( @entity2 ) related @entity6 and @entity1 in northwestern Greece. @entity0 AND METHODS: Single referral center retrospective study. The policy among all gastroenterologists of the area regarding medical treatment, @entity0 follow up and bowel surveillance strategies including risk factors is the same. RESULTS: We analyzed 1494 colonoscopies from 696 consecutive @entity2 @entity0 (494 UC). The follow up time [median, IQR] was 16 [8-23] years and the age at diagnosis was 28 [21-49] years. The number of @entity0 years at risk was 16.219. Disease location for UC was: pancolitis 761 (59%), @entity7 455 (35%), and @entity9 69 (6%). Disease location for @entity4 was: colitis 142 (66%), @entity10 45 (22%) and @entity3 21 (10%). Disease activity was in remission in 1240 (83%) of them. In total, 498 (72%) @entity0 were on @entity8 , 169(24%) on immunosuppression and 29 (4%) on biologicals. Biopsies were taken randomly in 1429 (96%) endoscopies and were targeted in 65 (4%) of them. We recorded 69 (9.4%) cases with @entity5 and 10 (1.4%) cases with @entity1 (9 in UC). No difference was found for @entity5 and @entity1 in @entity0 who followed up for 10-20 years or for more than 20 years. CONCLUSIONS: The prevalence of @entity5 and @entity1 is increased in UC compared to @entity4 but the prevalence of high-grade @entity5 is comparatively low. @entity1 prevalence is increasing after the first decade and then practically remains stable.

title: Prevalence of @entity2 related @entity5 and XXXX in 1500 colonoscopies from a referral center in northwestern Greece.

answer: @entity1


abstract: BACKGROUND: @entity8 ( @entity8 ) is the only treatment that interferes with the basic pathophysiological mechanisms of @entity1 and is widely used in the management of clinically significant respiratory IgE-mediated diseases. Nevertheless, until recently, information on the influence of @entity8 on the development of @entity1 has been scant. METHODS: One hundred consecutive @entity0 (45 males and 55 females, aged 6 to 69 years) with @entity5 and attending the allergy unit of a general hospital were selected. All had been diagnosed by clinical history and skin prick tests of @entity6 and/or @entity4 , were monosensitised (71 to Dermatophagoides spp, 22 to Parietaria judaica pollen and 7 to grass pollen) and had been followed up as outpatients between 1990-98. Sixty-six @entity0 had been treated with conventional @entity8 for at least 3 years, while thirty-four followed only environmental measures and drug treatment. @entity3 status (first-degree relatives), smoking, family pets (cat and/or @entity2 ), @entity7 and/or @entity4 symptom score and inhalant skin prick tests to the same aeroallergens were compared between baseline and after 3 to 5 years of treatment. RESULTS: No statistically-significant differences in the development of new sensitisations were observed between the two groups (36.4 % of @entity8 -treated @entity0 versus 38.2 % in control group, RR = 0.97, CI 95 %: 0.72-1.3). Smoking, family atopy history and pets did not appear to be risk factors for the development of neosensitisations (p < 0.05). Nevertheless, @entity8 -treated @entity0 presented a better clinical score than the control group, with improvements of 89.4 % and 61.8 %, respectively (p = 0.007). CONCLUSIONS: Three-year @entity8 did not protect against development of new sensitisations in monosensitised @entity6 or @entity4 . Smoking, family atopy history and pets were not associated with development of new sensitisations. Clinical score improved significantly in the @entity8 -treated group compared with drug-treated @entity0 .

title: Effects of specific immunotherapy on the development of new sensitisations in monosensitised XXXX .

answer: @entity0


abstract: OBJECTIVES: We sought to determine the relationship of contractile function to the transmural extent of @entity4 (TEI) in @entity0 with chronic @entity2 . BACKGROUND: In the setting of reperfused, chronic @entity3 ( @entity3 ), the relationship of contractile function to the TEI has not been established. METHODS: We studied function by cine magnetic resonance imaging (MRI) and the TEI by contrast-enhanced MRI in 31 @entity0 with @entity1 162 +/- 62 days after reperfused first @entity3 . RESULTS: Of all 516 segments with @entity3 , blinded observers were unable to detect abnormal thickening in 193 (37%), and wall thickening measured quantitatively in these segments was 66 +/- 28%. Of the 193 segments, 163 (84%) were @entity4 limited to the subendocardium. The average TEI reached 53% before half of the @entity0 had abnormal contractile function. When @entity0 with small @entity3 (< or =5% of total left ventricular [LV] mass) were excluded, the average TEI reached 43% before half the @entity0 had abnormal function. In subjects with small @entity3 (< or =5% of total LV mass [n = 13]), even segments with TEI >75% had normal function (14 of 14) because they were surrounded by normally moving neighbor segments. CONCLUSIONS: In the setting of reperfused chronic @entity3 , the TEI approaches 50% before contractile dysfunction can be systematically identified. Contractile function cannot be used to rule out chronic @entity3 .

title: Relationship of contractile function to transmural extent of XXXX in @entity0 with chronic @entity2 .

answer: @entity4


abstract: OBJECTIVES: We sought to determine the relationship of contractile function to the transmural extent of @entity4 (TEI) in @entity0 with chronic @entity2 . BACKGROUND: In the setting of reperfused, chronic @entity3 ( @entity3 ), the relationship of contractile function to the TEI has not been established. METHODS: We studied function by cine magnetic resonance imaging (MRI) and the TEI by contrast-enhanced MRI in 31 @entity0 with @entity1 162 +/- 62 days after reperfused first @entity3 . RESULTS: Of all 516 segments with @entity3 , blinded observers were unable to detect abnormal thickening in 193 (37%), and wall thickening measured quantitatively in these segments was 66 +/- 28%. Of the 193 segments, 163 (84%) were @entity4 limited to the subendocardium. The average TEI reached 53% before half of the @entity0 had abnormal contractile function. When @entity0 with small @entity3 (< or =5% of total left ventricular [LV] mass) were excluded, the average TEI reached 43% before half the @entity0 had abnormal function. In subjects with small @entity3 (< or =5% of total LV mass [n = 13]), even segments with TEI >75% had normal function (14 of 14) because they were surrounded by normally moving neighbor segments. CONCLUSIONS: In the setting of reperfused chronic @entity3 , the TEI approaches 50% before contractile dysfunction can be systematically identified. Contractile function cannot be used to rule out chronic @entity3 .

title: Relationship of contractile function to transmural extent of @entity4 in @entity0 with chronic XXXX .

answer: @entity2


abstract: OBJECTIVES: We sought to determine the relationship of contractile function to the transmural extent of @entity4 (TEI) in @entity0 with chronic @entity2 . BACKGROUND: In the setting of reperfused, chronic @entity3 ( @entity3 ), the relationship of contractile function to the TEI has not been established. METHODS: We studied function by cine magnetic resonance imaging (MRI) and the TEI by contrast-enhanced MRI in 31 @entity0 with @entity1 162 +/- 62 days after reperfused first @entity3 . RESULTS: Of all 516 segments with @entity3 , blinded observers were unable to detect abnormal thickening in 193 (37%), and wall thickening measured quantitatively in these segments was 66 +/- 28%. Of the 193 segments, 163 (84%) were @entity4 limited to the subendocardium. The average TEI reached 53% before half of the @entity0 had abnormal contractile function. When @entity0 with small @entity3 (< or =5% of total left ventricular [LV] mass) were excluded, the average TEI reached 43% before half the @entity0 had abnormal function. In subjects with small @entity3 (< or =5% of total LV mass [n = 13]), even segments with TEI >75% had normal function (14 of 14) because they were surrounded by normally moving neighbor segments. CONCLUSIONS: In the setting of reperfused chronic @entity3 , the TEI approaches 50% before contractile dysfunction can be systematically identified. Contractile function cannot be used to rule out chronic @entity3 .

title: Relationship of contractile function to transmural extent of @entity4 in XXXX with chronic @entity2 .

answer: @entity0


abstract: BACKGROUND: Coagulation plays an important part in @entity2 . Results of studies have shown that extremes in hypocoagulability protect against @entity2 . We have investigated overall mortality and @entity3 from cardiovascular causes in carriers of @entity5 , who in most cases have mildly @entity7 without clinical signs. METHODS: We followed-up a cohort of 1012 mothers of all known @entity0 with @entity5 in the Netherlands from birth to @entity3 , or the end-of-study date (41984 @entity0 years of follow-up). We obtained vital status and causes of @entity3 , if deceased, and compared overall and cause-specific mortality in our cohort with that in the general Dutch female population adjusted for age and calendar period by calculating the standardised mortality ratio (SMR). FINDINGS: Overall mortality was reduced by 22% (261 observed @entity3 , 333.74 expected; SMR 0.78 [95% CI 0.69-0.88]). @entity3 from @entity4 were reduced by 36% (39 observed @entity3 , 60.53 expected; SMR 0.64 [0.47-0.88]). We did not note decreased mortality for @entity1 (ischaemic and @entity6 combined) (28 observed @entity3 , 36.82 expected; SMR 0.76 [0.53-1.10]). A separate analysis of these two types of @entity1 was not possible. @entity0 in our cohort had an increased risk of @entity3 from extracranial @entity6 (5 observed @entity3 , 0.18 expected; SMR 27.78 [8.49-58.18]); however, the number of @entity3 from this cause was much lower than that for @entity4 . CONCLUSION: The results show that a mild @entity7 has a protective effect against fatal @entity4 .

title: Decreased mortality of @entity4 among carriers of XXXX .

answer: @entity5


abstract: BACKGROUND: Coagulation plays an important part in @entity2 . Results of studies have shown that extremes in hypocoagulability protect against @entity2 . We have investigated overall mortality and @entity3 from cardiovascular causes in carriers of @entity5 , who in most cases have mildly @entity7 without clinical signs. METHODS: We followed-up a cohort of 1012 mothers of all known @entity0 with @entity5 in the Netherlands from birth to @entity3 , or the end-of-study date (41984 @entity0 years of follow-up). We obtained vital status and causes of @entity3 , if deceased, and compared overall and cause-specific mortality in our cohort with that in the general Dutch female population adjusted for age and calendar period by calculating the standardised mortality ratio (SMR). FINDINGS: Overall mortality was reduced by 22% (261 observed @entity3 , 333.74 expected; SMR 0.78 [95% CI 0.69-0.88]). @entity3 from @entity4 were reduced by 36% (39 observed @entity3 , 60.53 expected; SMR 0.64 [0.47-0.88]). We did not note decreased mortality for @entity1 (ischaemic and @entity6 combined) (28 observed @entity3 , 36.82 expected; SMR 0.76 [0.53-1.10]). A separate analysis of these two types of @entity1 was not possible. @entity0 in our cohort had an increased risk of @entity3 from extracranial @entity6 (5 observed @entity3 , 0.18 expected; SMR 27.78 [8.49-58.18]); however, the number of @entity3 from this cause was much lower than that for @entity4 . CONCLUSION: The results show that a mild @entity7 has a protective effect against fatal @entity4 .

title: Decreased mortality of XXXX among carriers of @entity5 .

answer: @entity4


abstract: The aim of the present study was to clarify the involvement of protein kinase Cy (PKCy) in the facial @entity0 following @entity2 . We analyzed the change in PKCy expression in the trigeminal spinal subnucleus caudalis (Vc) and upper cervical spinal cord ( @entity6 ) following chronic @entity2 (ION-CCI). We also studied ION-CCI-mediated mechanical nocifensive behavior in @entity1 . The mechanical head-withdrawal threshold significantly decreased 1 to 14 days after ION-CCI compared with that before ION-CCI and in sham @entity1 . The expression of PKCy was significantly larger in the ipsilateral Vc compared with the contralateral side in ION-CCI @entity1 3, 7, and 14 days after ION-CCI. Intrathecal (i.t.) administration of the PKCy inhibitor @entity3 prevented an increase in the PKCy expression in the ipsilateral Vc. Moreover, i.t. administration of @entity3 annulled ION-CCI-mediated reduction in the head-withdrawal threshold. Taken together, these findings suggest that PKCy expression in the Vc played an important role in the mechanism of orofacial static mechanical @entity4 following @entity5 .

title: PKCgamma in Vc and @entity6 is involved in trigeminal XXXX .

answer: @entity0


abstract: The aim of the present study was to clarify the involvement of protein kinase Cy (PKCy) in the facial @entity0 following @entity2 . We analyzed the change in PKCy expression in the trigeminal spinal subnucleus caudalis (Vc) and upper cervical spinal cord ( @entity6 ) following chronic @entity2 (ION-CCI). We also studied ION-CCI-mediated mechanical nocifensive behavior in @entity1 . The mechanical head-withdrawal threshold significantly decreased 1 to 14 days after ION-CCI compared with that before ION-CCI and in sham @entity1 . The expression of PKCy was significantly larger in the ipsilateral Vc compared with the contralateral side in ION-CCI @entity1 3, 7, and 14 days after ION-CCI. Intrathecal (i.t.) administration of the PKCy inhibitor @entity3 prevented an increase in the PKCy expression in the ipsilateral Vc. Moreover, i.t. administration of @entity3 annulled ION-CCI-mediated reduction in the head-withdrawal threshold. Taken together, these findings suggest that PKCy expression in the Vc played an important role in the mechanism of orofacial static mechanical @entity4 following @entity5 .

title: PKCgamma in Vc and XXXX is involved in trigeminal @entity0 .

answer: @entity6


abstract: BACKGROUND: The aim of this study was to assess the salivary content of lipid peroxidation and antioxidants in @entity0 with @entity2 2 @entity1 . METHOD: We studied 25 @entity0 with @entity2 2 @entity1 and other 25 age- and sex-matched health control. To evaluate the oxidative status we measured the levels of @entity6 ( @entity8 ) in the saliva and serum of all @entity0 . Lipid profile was also estimated through measuring total @entity3 , @entity7 , low-density lipoprotein @entity3 (LDL-C), high-density lipoprotein @entity3 (HDL-C) and very low-density lipoprotein @entity3 (VLDL-C) levels. Antioxidant levels were also assessed through measuring the salivary and serum concentration of @entity5 , @entity4 dismutase and @entity9 ( @entity10 ). RESULTS: The high concentration of lipid fractions in saliva usually follows that recorded in serum. Salivary @entity8 levels, a product of lipid peroxidation, were significantly increased among diabetics together with @entity5 . However, @entity10 levels were similar to those of the control group. CONCLUSION: Lipid peroxidation and antioxidant parameters assessed in saliva of @entity1 @entity0 may be of great importance in evaluating the disease activity and severity. The increase in lipid peroxidation and the tendency of antioxidants to rise in @entity1 is probably due to an adaptive response to the pro-oxidant status of @entity1 .

title: Oxidative stress, antioxidant status and lipid profile in the saliva of XXXX 2 diabetics.

answer: @entity2


abstract: OBJECTIVES: @entity7 (Deskar, Marnac Inc., Dallas, TX), @entity7 , is a broad-spectrum, noncytotoxic, oral antifibrotic agent that is reported to inhibit or block the action of cytokine growth factors: transforming growth factor beta1, platelet-derived growth factor, epidermal growth factor, and fibroblast growth factor, and to prevent formation of new @entity3 . METHODS: We enrolled 10 @entity0 and four @entity0 with extensive @entity6 ( @entity6 )-associated @entity8 in a 2-yr open-label treatment trial with oral @entity7 . Imaging of desmoids was conducted at baseline and 6, 12, and 24 months. RESULTS: No drug @entity4 or drug intolerance was encountered. Seven @entity0 dropped out (three because of @entity2 ), and seven continued for at least 18 months. Of those that continued, two had partial but significant reduction in the size of all desmoids beginning in the first 6 months of treatment, and two others experienced relief of symptoms without change in desmoid size. Three @entity0 experienced no change in @entity1 size or symptoms. CONCLUSIONS: @entity7 is well tolerated by @entity0 with @entity6 -associated @entity5 . Some @entity0 with @entity6 treated with @entity7 had regression of @entity1 , some had progression, and some had no response. @entity0 with rapidly growing @entity1 did not respond to @entity7 . A placebo-controlled trial is needed to determine whether there is a subset of @entity0 for whom @entity7 may result in partial shrinkage of @entity5 , because the natural history of @entity5 is not predictable or understood.

title: @entity5 in XXXX : a pilot project evaluating efficacy of treatment with @entity7 .

answer: @entity6


abstract: OBJECTIVES: @entity7 (Deskar, Marnac Inc., Dallas, TX), @entity7 , is a broad-spectrum, noncytotoxic, oral antifibrotic agent that is reported to inhibit or block the action of cytokine growth factors: transforming growth factor beta1, platelet-derived growth factor, epidermal growth factor, and fibroblast growth factor, and to prevent formation of new @entity3 . METHODS: We enrolled 10 @entity0 and four @entity0 with extensive @entity6 ( @entity6 )-associated @entity8 in a 2-yr open-label treatment trial with oral @entity7 . Imaging of desmoids was conducted at baseline and 6, 12, and 24 months. RESULTS: No drug @entity4 or drug intolerance was encountered. Seven @entity0 dropped out (three because of @entity2 ), and seven continued for at least 18 months. Of those that continued, two had partial but significant reduction in the size of all desmoids beginning in the first 6 months of treatment, and two others experienced relief of symptoms without change in desmoid size. Three @entity0 experienced no change in @entity1 size or symptoms. CONCLUSIONS: @entity7 is well tolerated by @entity0 with @entity6 -associated @entity5 . Some @entity0 with @entity6 treated with @entity7 had regression of @entity1 , some had progression, and some had no response. @entity0 with rapidly growing @entity1 did not respond to @entity7 . A placebo-controlled trial is needed to determine whether there is a subset of @entity0 for whom @entity7 may result in partial shrinkage of @entity5 , because the natural history of @entity5 is not predictable or understood.

title: @entity5 in @entity6 : a pilot project evaluating efficacy of treatment with XXXX .

answer: @entity7


abstract: OBJECTIVES: @entity7 (Deskar, Marnac Inc., Dallas, TX), @entity7 , is a broad-spectrum, noncytotoxic, oral antifibrotic agent that is reported to inhibit or block the action of cytokine growth factors: transforming growth factor beta1, platelet-derived growth factor, epidermal growth factor, and fibroblast growth factor, and to prevent formation of new @entity3 . METHODS: We enrolled 10 @entity0 and four @entity0 with extensive @entity6 ( @entity6 )-associated @entity8 in a 2-yr open-label treatment trial with oral @entity7 . Imaging of desmoids was conducted at baseline and 6, 12, and 24 months. RESULTS: No drug @entity4 or drug intolerance was encountered. Seven @entity0 dropped out (three because of @entity2 ), and seven continued for at least 18 months. Of those that continued, two had partial but significant reduction in the size of all desmoids beginning in the first 6 months of treatment, and two others experienced relief of symptoms without change in desmoid size. Three @entity0 experienced no change in @entity1 size or symptoms. CONCLUSIONS: @entity7 is well tolerated by @entity0 with @entity6 -associated @entity5 . Some @entity0 with @entity6 treated with @entity7 had regression of @entity1 , some had progression, and some had no response. @entity0 with rapidly growing @entity1 did not respond to @entity7 . A placebo-controlled trial is needed to determine whether there is a subset of @entity0 for whom @entity7 may result in partial shrinkage of @entity5 , because the natural history of @entity5 is not predictable or understood.

title: XXXX in @entity6 : a pilot project evaluating efficacy of treatment with @entity7 .

answer: @entity5


abstract: PURPOSE: To report our experience with @entity5 in 2nd-, 3rd- and 4th-line therapy for @entity0 with @entity4 ( @entity4 ). @entity0 AND METHODS: In our prospectively maintained @entity1 registry, we identified 6 @entity4 @entity0 with @entity5 in >1st-line systemic therapy. @entity0 were followed by weekly clinical and laboratory examination during admission of @entity5 . Re-staging with chest CT and abdominal MRI was performed every 3 months. RESULTS: We observed excellent response rates. Progression-free survival (PFS) ranged from 6 to 40 months with a median of 15 months. Treatment was generally well tolerated. However, @entity2 was observed in 4 of 6 @entity0 . Drug-related @entity2 led to severe @entity3 , with the result that treatment with @entity5 had to be interrupted for a short period of time in 2 @entity0 and discontinued in 1 @entity0 . CONCLUSIONS: @entity5 proved to be a very good treatment option in 2nd- to 4th-line therapy with excellent response rates and manageable side effects. The incidence of @entity2 must not be underestimated.

title: Initial experience with @entity5 in 2nd-, 3rd- and 4th-line therapy for metastatic XXXX : good clinical response.

answer: @entity4


abstract: PURPOSE: To report our experience with @entity5 in 2nd-, 3rd- and 4th-line therapy for @entity0 with @entity4 ( @entity4 ). @entity0 AND METHODS: In our prospectively maintained @entity1 registry, we identified 6 @entity4 @entity0 with @entity5 in >1st-line systemic therapy. @entity0 were followed by weekly clinical and laboratory examination during admission of @entity5 . Re-staging with chest CT and abdominal MRI was performed every 3 months. RESULTS: We observed excellent response rates. Progression-free survival (PFS) ranged from 6 to 40 months with a median of 15 months. Treatment was generally well tolerated. However, @entity2 was observed in 4 of 6 @entity0 . Drug-related @entity2 led to severe @entity3 , with the result that treatment with @entity5 had to be interrupted for a short period of time in 2 @entity0 and discontinued in 1 @entity0 . CONCLUSIONS: @entity5 proved to be a very good treatment option in 2nd- to 4th-line therapy with excellent response rates and manageable side effects. The incidence of @entity2 must not be underestimated.

title: Initial experience with XXXX in 2nd-, 3rd- and 4th-line therapy for metastatic @entity4 : good clinical response.

answer: @entity5


abstract: Based on the favorable safety profile and the independent activity of rituximab in @entity6 , we evaluated its efficacy and @entity2 after @entity1 ( @entity1 ) and autologous hematopoietic cell transplantation (HCT). Thirty-five @entity0 with diffuse large cell (25 @entity0 ), mantle cell (3 @entity0 ), transformed (3 @entity0 ), or other (4 @entity0 ) subtypes of @entity6 received @entity1 followed by a purged autologous graft. The rituximab schedule was 4 weekly infusions (375 mg/m(2)) starting at day 42 after HCT and, for @entity0 5 to 35, a second 4-week course 6 months after HCT. All planned therapy was completed in 29 @entity0 . With 30 months' median follow-up, the 2-year event-free survival (EFS) rate was 83% and the @entity4 ( @entity4 ) rate was 88%. For 21 @entity0 with relapsed or @entity3 , the EFS rate was 81% and the @entity4 rate was 85%. Grades 3 to 4 @entity5 occurred in 19 (54%) @entity0 . A prospective study of immune reconstitution included measurements of lymphocyte subsets, immunoglobulins, and response to vaccination. Serious infections were not observed despite delayed B-cell recovery in all @entity0 and suppressed immunoglobulin G (IgG) levels and low pneumococcus antibody titers in a subset. Rituximab after @entity1 and HCT is feasible, and these phase 2 data support the current US Intergroup phase 3 trial in recurrent/refractory @entity7 .

title: Rituximab as adjuvant to XXXX and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma.

answer: @entity1


abstract: BACKGROUND: Behavioral dyscontrol and violations of treatment contracts are serious clinical problems during psychotherapy, especially in treating @entity0 with @entity3 . However, little is known about predictors of these treatment-interfering phenomena. OBJECTIVE: To identify psychodynamic personality characteristics that can interfere with the psychotherapy process as indicated by treatment-disrupting behaviors. METHODS: Sociodemographic characteristics, descriptive psychiatric diagnoses, and psycho-dynamic characteristics were assessed in 89 inpatients with @entity3 in psychotherapeutic treatment. Psychodynamic characteristics were assessed with the Develop mental Profile (DP). DP variables were used to predict impulsive acts, anger outbursts, para-suicidal behaviors, and contract violations. Incremental value was established. RESULTS: In this sample, 4 out of 5 @entity0 engaged in treatment-interfering behaviors during the first 3 months of therapy. In general, treatment-disrupting behaviors were not predicted by baseline DSM-IV @entity1 . In contrast, @entity2 , anger outbursts, and contract violations were significantly predicted by psychodynamic variables, especially the DP levels Fragmentation and Egocentricity. DP variables accounted for an incremental predictive value of 23% for treatment-disrupting behaviors, over and above demographics and descriptive diagnoses. Para-suicidal gestures were not predicted by either DSM-IV diagnoses or psychodynamic variables. CONCLUSION: Psychodynamic personality variables significantly predicted @entity2 , outbursts of anger, and treatment contract violations during psychotherapeutic treatment. The amount of explained variance and incremental value was substantial. These findings support the relevance of psychodynamic assessment in clinical practice. (Journal of Psychiatric Practice. 2011;17:21-34).

title: Treatment-disrupting behaviors during psychotherapy of @entity0 with XXXX : the predictive power of psychodynamic personality diagnosis.

answer: @entity3


abstract: BACKGROUND: Behavioral dyscontrol and violations of treatment contracts are serious clinical problems during psychotherapy, especially in treating @entity0 with @entity3 . However, little is known about predictors of these treatment-interfering phenomena. OBJECTIVE: To identify psychodynamic personality characteristics that can interfere with the psychotherapy process as indicated by treatment-disrupting behaviors. METHODS: Sociodemographic characteristics, descriptive psychiatric diagnoses, and psycho-dynamic characteristics were assessed in 89 inpatients with @entity3 in psychotherapeutic treatment. Psychodynamic characteristics were assessed with the Develop mental Profile (DP). DP variables were used to predict impulsive acts, anger outbursts, para-suicidal behaviors, and contract violations. Incremental value was established. RESULTS: In this sample, 4 out of 5 @entity0 engaged in treatment-interfering behaviors during the first 3 months of therapy. In general, treatment-disrupting behaviors were not predicted by baseline DSM-IV @entity1 . In contrast, @entity2 , anger outbursts, and contract violations were significantly predicted by psychodynamic variables, especially the DP levels Fragmentation and Egocentricity. DP variables accounted for an incremental predictive value of 23% for treatment-disrupting behaviors, over and above demographics and descriptive diagnoses. Para-suicidal gestures were not predicted by either DSM-IV diagnoses or psychodynamic variables. CONCLUSION: Psychodynamic personality variables significantly predicted @entity2 , outbursts of anger, and treatment contract violations during psychotherapeutic treatment. The amount of explained variance and incremental value was substantial. These findings support the relevance of psychodynamic assessment in clinical practice. (Journal of Psychiatric Practice. 2011;17:21-34).

title: Treatment-disrupting behaviors during psychotherapy of XXXX with @entity3 : the predictive power of psychodynamic personality diagnosis.

answer: @entity0


abstract: @entity8 modulates various vascular functions such as vasodilatation and anti- @entity2 . The local concentration of @entity8 in the vicinity of @entity8 receptors is fine tuned by 2 classes of @entity9 transporters: equilibrative @entity9 transporters (ENTs) and concentrative @entity9 transporters (CNTs). In vascular smooth muscle cells, 95% of @entity8 transport is mediated by @entity14 and the rest by @entity17 . In endothelial cells, 60%, 10%, and 30% of @entity8 transport are mediated by @entity14 , @entity17 , and @entity16 , respectively. In vitro studies show that @entity5 per se increases the expression level of @entity14 via mitogen-activating protein kinase-dependent pathways. Similar results have been demonstrated in @entity1 animal models. @entity4 is associated with the increased expression of @entity16 . It has been speculated that the increase in the activities of @entity14 and @entity16 may reduce the availability of @entity8 to @entity8 receptors, thereby weakening the vascular functions of @entity8 . This may explain why @entity0 with @entity1 and @entity4 suffer greater morbidity from @entity3 and @entity7 . No oral hypoglycemic agents can inhibit ENTs, but an exception is @entity12 (a @entity15 that has been withdrawn from the market). ENTs are also sensitive to @entity13 -type @entity6 -channel blockers, particularly @entity11 , which can inhibit @entity14 in the nanomolar range. Those @entity6 -channel blockers are noncompetitive inhibitors of ENTs, probably working through the reversible interactions with allosteric sites. The nonsteroidal anti-inflammatory drug sulindac @entity10 is a competitive inhibitor of @entity14 . In addition to their original pharmacological actions, it is believed that the drugs mentioned above may regulate vascular functions through potentiation of the effects of @entity8 .

title: Physiological and pharmacological roles of vascular XXXX transporters.

answer: @entity9


abstract: BACKGROUND AND OBJECTIVE: The serum paraoxonase and arylesterase activities are related to @entity6 . However, there are a few data about the association of paraoxonase and arylesterase activities with in-stent @entity4 (ISR). The aim of this study was to evaluate the relationship between paraoxonase and arylesterase activities and ISR in @entity0 with bare metal stent (BMS). MATERIALS AND METHODS: Thirty-one @entity0 with normal coronary artery (group 1) and 60 with BMS were enrolled in this observational study. According to the ISR, the @entity0 were classified as group 2, without the ISR (n=29) and group 3, with the ISR (n=31). Serum paraoxonase and arylesterase activities were measured spectrophotometrically. RESULTS: The paraoxonase and arylesterase activities were lower in @entity0 with BMS than in the individuals with normal coronary artery (P < 0.001 and P = 0.001, respectively). The enzyme activities were also higher in @entity0 without ISR than with ISR (both of P < 0.001). In bivariate correlation analyses in @entity0 with BMS, ISR shows significant positive correlations with the presence of @entity2 and @entity5 , @entity1 , and stent length, but shows negative correlations with @entity1 stent diameter, high-density lipoprotein @entity3 , and paraoxonase and arylesterase activities. In regression analysis, ISR is independently associated with paraoxonase and arylesterase activities (b = -0.216, P = 0.038 and b = -0.452, P < 0.001, respectively), @entity1 (b = -0.251, P = 0.013), and stent diameter (b = -0.192, P = 0.024) in @entity0 with BMS. CONCLUSION: Our study shows that decreased paraoxonase and arylesterase activities play a significant role in ethiopathogenesis ISR in @entity0 with BMS.

title: Paraoxonase and arylesterase activities in stent XXXX in bare metal stent.

answer: @entity4


abstract: STUDY DESIGN: Biomechanics of @entity0 intervertebral discs before and after nucleotomy. OBJECTIVE: To noninvasively quantify the effect of nucleotomy on internal strains under axial compression in flexion, neutral, and extension positions, and to determine whether the change in strains depended on degeneration. SUMMARY OF BACKGROUND DATA: Herniation and nucleotomy may accelerate the progression of @entity2 . Removal of nucleus pulposus (NP) tissue has resulted in altered disc mechanics in vitro, including a decrease in internal pressure and an increase in the deformations at physiologically relevant strains. We recently presented a technique to quantify internal disc strains using magnetic resonance imaging (MRI). METHODS: Degeneration was quantitatively assessed by the T1   relaxation time in the NP. Samples were prepared from @entity0 levels L3-L4 and/or L4-L5. A 1000-N compressive load was applied while in the magnetic resonance scanner. Nucleotomy was performed by removing 2 g of NP through the posterior-lateral annulus fibrosus (AF). The discs were rehydrated, reimaged, and retested. The analyzed parameters include @entity1 , AF radial bulge, and strains. RESULTS.: The @entity1 was more compressive after nucleotomy. In the neutral position, the @entity1 after nucleotomy correlated with degeneration (as quantified by T1   in the NP), with minimal alteration in nondegenerated discs. Nucleotomy altered the radial displacements and strains in the neutral position, such that the inner AF radial bulge decreased and the radial strains were more tensile in the lateral AF and less tensile in the posterior AF. In the bending loading positions the radial strains were not affected by nucleotomy. CONCLUSION: Nucleotomy alters the internal radial and axial AF strains in the neutral position, which may leave the AF vulnerable to damage and microfractures. In bending, the effects of nucleotomy were minimal, likely due to more of the applied load being directed over the AF. Some of the nucleotomy effects are modulated by degeneration, where the mechanical effect of nucleotomy was magnified in degenerated discs and may further induce mechanical damage and degeneration.

title: The effect of nucleotomy and the dependence of degeneration of XXXX intervertebral disc strain in axial compression.

answer: @entity0


abstract: BACKGROUND: Limited data exist regarding the long-term outcomes of EMR compared with gastrectomy. OBJECTIVE: To compare the long-term outcomes after EMR and surgery. DESIGN: Retrospective analysis with propensity-score matching. SETTING: Tertiary care center. @entity0 : This study involved 215 @entity0 with @entity2 completely removed by EMR and 843 @entity0 who underwent curative surgical resection between January 1997 and August 2002. Propensity-score matching yielded 551 matched @entity0 . INTERVENTIONS: EMR versus surgery. MAIN OUTCOME MEASUREMENTS: Death and recurrence. RESULTS: In the matched cohort, there were no significant between-group differences in the risk of @entity1 (hazard ratio [HR] for the EMR group 1.39; 95% CI, 0.87-2.23) or recurrence (HR 1.18; 95% CI, 0.22-6.35). Although @entity0 who underwent EMR had higher risk of metachronous @entity2 (HR 6.72; 95% CI, 2.00-22.58), all recurrent or metachronous @entity2 after EMR were successfully re-treated without affecting overall survival. Although complication rates were similar (odds ratio 0.84; 95% CI, 0.41-1.70), there were no mortalities in the EMR group compared with 2 in the surgery group. The EMR group had a significantly shorter hospital stay (median 8 days, interquartile range [IQR] 6-11 days vs 15 days, IQR 12-19 days; P<.001) and lower cost of care ( 2049, IQR  1586-2425 vs  4042, IQR  3458-4959; P<.001). LIMITATIONS: Retrospective, nonrandomized study. CONCLUSIONS: EMR was comparable to surgery in terms of risk of @entity1 and recurrence. Because of its lower medical costs and shorter duration of hospital stay, EMR has advantages over surgery.

title: EMR versus gastrectomy for XXXX : comparison of long-term outcomes.

answer: @entity2


abstract: BACKGROUND: The influence of regional right ventricular (RV) dysfunction on the accuracy of Doppler tissue imaging (DTI) assessment of global RV function is unknown. The objective of this study was to determine the effect of regional dysfunction of the @entity3 ( @entity3 ) on the correlations between RV DTI indices and cardiac magnetic resonance (CMR) measurements of global RV function in @entity0 with repaired tetralogy of Fallot. METHODS: Consecutive @entity0 with repaired tetralogy of Fallot who underwent echocardiography with DTI of the right ventricle and CMR within 4 weeks of each other were retrospectively analyzed. RV DTI measurements were obtained from the lateral wall at the level of the tricuspid valve annulus. CMR measurements included end-diastolic and end-systolic volumes, @entity1 volume, and ejection fraction (EF) of the entire right ventricle and measured separately for the RV sinus and @entity3 segments. RESULTS: The median age of the 51 @entity0 included was 19 years (range, 9.7-71.6 years), and the median interval between echocardiography and CMR was 0 days. The mean RV free wall peak S', isovolumic acceleration, and global, sinus, and @entity3 EFs were 8.4    2.0 cm/s, 102    37 cm/s(2), and 46.1    9.8%, 47.9    9.9%, and 33    13.1%, respectively. The correlation between peak S' and global RV EF was weak (r  = 0.23) in @entity0 with @entity2 ( @entity3 EF <30%) but higher (r  = 0.66) in those with @entity3 EFs >= 30%. Peak S' >= 8.4 cm/s (area under the receiver operating characteristic curve, 0.77) and isovolumic acceleration >= 95 cm/s(2) (area under the receiver operating characteristic curve, 0.68) best discriminated between @entity0 with global RV EFs >45% and <45%. CONCLUSIONS: In this group of @entity0 with repaired TOF, RV DTI indices showed reasonable correlation with CMR-derived global RV EF, but this correlation was substantially weaker in those with moderate and severe dysfunction of the @entity3 . Peak S' <8.4 cm/s and isovolumic acceleration <95cm/s(2) by DTI should prompt an evaluation of RV function by CMR.

title: Regional dysfunction of the right ventricular outflow tract reduces the accuracy of Doppler tissue imaging assessment of global right ventricular systolic function in XXXX with repaired tetralogy of Fallot.

answer: @entity0


abstract: @entity13 is frequently fatal or leads to severe @entity1 . Complications such as @entity11 , resulting in @entity10 , should be anticipated and dealt with promptly. Our aim was to demonstrate the complications of @entity8 by @entity5 ( @entity5 ) in @entity0 who deteriorated despite therapy. We studied 13 @entity0 between the ages of 1 day and 32 months who presented with symptoms ranging from @entity4 and @entity6 to @entity7 , @entity3 and @entity9 due to @entity13 , performing MRI, including @entity5 , 2-5 days after presentation. @entity10 were found on @entity5 in 12 of the 13, most commonly in the frontal lobes (in 10). Global involvement was seen in four @entity0 , three of whom died; the fourth had a very poor outcome. In one case abnormalities on @entity5 were due to @entity12 . We diagnosed @entity11 in three of five @entity0 studied with MRA. We think @entity5 an important part of an MRI study in @entity0 with @entity8 . Small @entity2 due to @entity11 can lead to tissue damage not easily recognized on routine imaging and @entity5 can be used to confirm that extra-axial collections represent empyemas.

title: Diffusion-weighted imaging in acute XXXX in infancy.

answer: @entity13


abstract: @entity0 has @entity4 proportions in all developed countries and many of the urban centres of the developing world. It is the most frequent @entity1 site in Singapore, accounting for 23.4% (623 cases) of all @entity1 deaths and nearly 5% of all causes in 1982. Based on incidence data for 1968-1977, among males, there was an average of about 330 cases diagnosed each year, giving an annual incidence rate of 30.7 per 100,000 and a proportion of 21% against all sites. Among females, there was an average of about 115 cases, with the incidence rate at 11.2 and the proportion 10.3% (ranking third behind breast and cervix). The risks among the Chinese were more than double those of the other ethnic groups. The Hokkien (73.2 per 100,000) and Teochew (67.0) males had one of the highest age-standardized incidence rates in the world. Most of the cases were of the @entity3 type. Among the females, the Cantonese (28.5) had about double the risks compared to the other dialect groups, and the rate was among the highest in the world. @entity2 accounted for almost 50% of the cases. The relevant host and environmental factors associated with @entity0 are discussed. Without doubt, cigarette smoking is the most important risk factor. The ultimate solution to this problem must lie in an effective smoking control programme, besides much-needed improvements in early diagnosis and treatment of the disease.

title: The epidemiology of XXXX in Singapore.

answer: @entity0


abstract: @entity5 ( @entity5 ) is a proposed new diagnostic criteria in the DSM-IV, cited as an example of an @entity3 Not Otherwise Specified (NOS). The phrase Binge Eating was introduced over 35 years ago to describe problematic behavior found in a subgroup of overweight individuals, and as a subgroup of @entity4 . The defining characteristics of @entity5 @entity0 are consumptions of an objectively large amount of food in discrete time periods, a lack of control during eating episodes and a lack of compensatory behavior binge. BEDs affect approximately 30% of @entity1 individuals seeking treatment. The binge eaters represent a distinct subgroup among the @entity1 with higher prevalence of comorbid @entity2 , as well as higher rates of eating pathology, as compared to normal @entity1 @entity0 . Several researches suggested that individuals use binge eating as a means of coping with emotional distress. In addition, the @entity5 represents a distinct subgroup among @entity4 with lower comorbid @entity2 , eating pathology and @entity2 . The present paper will review this proposed syndrome and will discuss the question of whether it is a distinct subgroup of @entity1 @entity0 or a distinct subgroup of @entity4 @entity0 , or a new diagnostic category. This diagnostic dilemma is discussed in light of clinical and empirical literature. Clinical and therapeutic implications are presented and ideas for future research are proposed.

title: [ @entity5 ( XXXX )--new diagnostic category].

answer: @entity5


abstract: @entity5 ( @entity5 ) is a proposed new diagnostic criteria in the DSM-IV, cited as an example of an @entity3 Not Otherwise Specified (NOS). The phrase Binge Eating was introduced over 35 years ago to describe problematic behavior found in a subgroup of overweight individuals, and as a subgroup of @entity4 . The defining characteristics of @entity5 @entity0 are consumptions of an objectively large amount of food in discrete time periods, a lack of control during eating episodes and a lack of compensatory behavior binge. BEDs affect approximately 30% of @entity1 individuals seeking treatment. The binge eaters represent a distinct subgroup among the @entity1 with higher prevalence of comorbid @entity2 , as well as higher rates of eating pathology, as compared to normal @entity1 @entity0 . Several researches suggested that individuals use binge eating as a means of coping with emotional distress. In addition, the @entity5 represents a distinct subgroup among @entity4 with lower comorbid @entity2 , eating pathology and @entity2 . The present paper will review this proposed syndrome and will discuss the question of whether it is a distinct subgroup of @entity1 @entity0 or a distinct subgroup of @entity4 @entity0 , or a new diagnostic category. This diagnostic dilemma is discussed in light of clinical and empirical literature. Clinical and therapeutic implications are presented and ideas for future research are proposed.

title: [ XXXX ( @entity5 )--new diagnostic category].

answer: @entity5


abstract: @entity7 are vasodilators of venous and arterial smooth muscle commonly prescribed both for @entity4 and @entity3 . Primarily venodilators, @entity7 also affect the systemic circulation if administered in sufficient dosage. In the coronary circulation, the principal effect is on the large epicardial and collateral vessels. Blood is shunted toward the @entity2 subendocardium. In the majority of @entity0 with @entity4 , relief of symptoms by @entity7 is primarily due to hemodynamic effects on preload and afterload, unless the @entity0 has @entity6 . In @entity0 with @entity3 , @entity7 decrease the resistance to the emptying of blood from the left ventricle as well as the filling pressure. @entity7 are relatively well tolerated, except for an initial throbbing @entity1 which rapidly resolves as tolerance develops. @entity7 are available in a multitude of forms including sublingual, oral, topical, transmucosal, intravenous, and spray preparations. Oral preparations undergo a first-pass effect in the liver, requiring larger doses. Other forms avoid this problem by direct transdermal absorption or the intravenous route. The latter has the advantage of rapid administration and ease of titration. The choice of @entity5 depends upon the clinical situation.

title: @entity5 therapy in XXXX and @entity3 .

answer: @entity4


abstract: @entity7 are vasodilators of venous and arterial smooth muscle commonly prescribed both for @entity4 and @entity3 . Primarily venodilators, @entity7 also affect the systemic circulation if administered in sufficient dosage. In the coronary circulation, the principal effect is on the large epicardial and collateral vessels. Blood is shunted toward the @entity2 subendocardium. In the majority of @entity0 with @entity4 , relief of symptoms by @entity7 is primarily due to hemodynamic effects on preload and afterload, unless the @entity0 has @entity6 . In @entity0 with @entity3 , @entity7 decrease the resistance to the emptying of blood from the left ventricle as well as the filling pressure. @entity7 are relatively well tolerated, except for an initial throbbing @entity1 which rapidly resolves as tolerance develops. @entity7 are available in a multitude of forms including sublingual, oral, topical, transmucosal, intravenous, and spray preparations. Oral preparations undergo a first-pass effect in the liver, requiring larger doses. Other forms avoid this problem by direct transdermal absorption or the intravenous route. The latter has the advantage of rapid administration and ease of titration. The choice of @entity5 depends upon the clinical situation.

title: XXXX therapy in @entity4 and @entity3 .

answer: @entity5


abstract: @entity7 are vasodilators of venous and arterial smooth muscle commonly prescribed both for @entity4 and @entity3 . Primarily venodilators, @entity7 also affect the systemic circulation if administered in sufficient dosage. In the coronary circulation, the principal effect is on the large epicardial and collateral vessels. Blood is shunted toward the @entity2 subendocardium. In the majority of @entity0 with @entity4 , relief of symptoms by @entity7 is primarily due to hemodynamic effects on preload and afterload, unless the @entity0 has @entity6 . In @entity0 with @entity3 , @entity7 decrease the resistance to the emptying of blood from the left ventricle as well as the filling pressure. @entity7 are relatively well tolerated, except for an initial throbbing @entity1 which rapidly resolves as tolerance develops. @entity7 are available in a multitude of forms including sublingual, oral, topical, transmucosal, intravenous, and spray preparations. Oral preparations undergo a first-pass effect in the liver, requiring larger doses. Other forms avoid this problem by direct transdermal absorption or the intravenous route. The latter has the advantage of rapid administration and ease of titration. The choice of @entity5 depends upon the clinical situation.

title: @entity5 therapy in @entity4 and XXXX .

answer: @entity3


abstract: OBJECTIVE: @entity6 is an @entity5 . It is characterized by distal muscle involvement, especially the gastrocnemius and soleus. The disease starts with @entity4 and @entity2 of the @entity3 . MATERIAL AND METHODS: Here we report on 2 @entity0 , brother and sister, from a Turkish family. Onset of the disease was at the age of 20 and 26 years of age, respectively. In both siblings, there was an early and predominant involvement of the distal muscles of the lower limbs. Creatine kinase activity was elevated 50- to 100-fold above normal values. RESULTS: Electromyography revealed a @entity1 pattern. Histology of the biceps muscles indicated some @entity1 changes consistent with @entity5 . Occurrence in only these 2 siblings with no other family members was indicative of an autosomal recessive inheritance. CONCLUSIONS: We describe the distinctive clinical features in 2 siblings of a Turkish family with MM as differential diagnosis and histological change.

title: XXXX of the Miyoshi type.

answer: @entity5


abstract: Different antidepressant drugs are currently used for the treatment of @entity4 in @entity2 @entity1 , such as second-generation antidepressants and, recently, the extracts of Hypericum perforatum. These agents are susceptible to metabolically-based drug interactions with anticancer drugs. The aim of the present article is to provide an updated review of clinically relevant metabolic drug interactions between selected anticancer drugs and antidepressants, focusing on selective @entity6 reuptake inhibitors (SSRIs) and Hypericum extract. SSRIs can cause pharmacokinetic interactions through their in vitro ability to inhibit one or more cytochrome P450 isoenzymes (CYPs). SSRIs differ in their potential for metabolic drug interactions with anticancer drugs. @entity9 and @entity8 are potent inhibitors of @entity15 and administration of these SSRIs reduces the clinical benefit of an anticancer drug, such as @entity5 , by decreasing the formation of active metabolites of this drug. @entity1 with @entity0 who receive @entity8 in combination with @entity5 are at increased risk for @entity3 . Other SSRIs, including @entity7 , @entity7 , are weak or negligible inhibitors of @entity15 and are less likely to interact with anticancer drugs, while @entity14 causes significant inhibition of this isoform only at high doses. Hypericum extract, by inducing both the @entity16 and the @entity11 ( @entity11 ), can reduce the plasma concentrations of different antineoplastic agents such as @entity12 , @entity13 and @entity10 , thus reducing the clinical efficacy of these drugs. Although these interactions are often predictable, the use of @entity9 , @entity8 and Hypericum extract should be avoided in @entity2 @entity1 .

title: Metabolic drug interactions between antidepressants and anticancer drugs: focus on selective XXXX reuptake inhibitors and hypericum extract.

answer: @entity6


abstract: In order to examine the appearance of synaptic vesicles and to correlate it with the formation of the synaptic layers, we have determined the staining pattern of a murine monoclonal antibody (SV 48) to a synaptic vesicle-associated protein in developing @entity0 retina. The antigen was detected by the indirect immunofluorescence technique using cryostat sections of @entity2 -fixed retinas. In the adult retina, the antibody stained both the outer plexiform (OPL) and the @entity1 ( @entity1 ). The nuclear layers and the nerve fiber layer (NFL) were devoid of any staining. In prenatal and early postnatal (P) retinas, the antibody stained two bands which corresponded to the respective locations of the NFL and @entity1 . Staining in the NFL increased until P-4 and began to decline subsequently, and by @entity4 little staining was left in this layer. In contrast, in the @entity1 , the intensity of staining increased gradually and leveled off by P-10. In the outer retina, a band of fluorescence corresponding to the OPL was first observed at @entity3 and increased in intensity up to P-10. Immunoblotting studies showed that the major immunoreactive material from adult and embryonic retinas had a Mr approximately 65,000-67,000. As expected from its developmental pattern, all bands appeared initially in the central retina and subsequently in the peripheral retina. Our results show that the synaptic vesicle-protein is present in the nerve fiber layer before synaptogenesis in the central nervous system. Subsequently, the protein is lost from the NFL, possibly as a consequence of synapse formation.

title: Developmental expression of a synaptic vesicle-specific protein in the XXXX retina.

answer: @entity0


abstract: The study evaluated the effects of @entity1 use and machine enclosure on workers' exposure to bacteria, endotoxins, and @entity0 in the use of metalworking fluids (MWF). Concentrations of @entity1 and bacterial contaminants were monitored in bulk samples of MWF from two machines in one workplace. One of the machines was used normally; @entity1 was added to the other when needed. Air sampling was used to estimate workers' exposure to endotoxins at 18 workplaces near enclosed and open machines. Concentrations of @entity1 in MWF and @entity0 in the air were measured. Some recirculating local exhaust ventilation systems were also tested. The endotoxin and bacteria concentrations in the biocide test of MWF rapidly increased when the biocide levels decreased below 500 ppm. Airborne concentrations of endotoxins were substantially lower near enclosed machines than near open ones. Concentrations of airborne @entity0 were below the Finnish occupational exposure limit at the existing levels of @entity1 in MWF. Concentrations of @entity1 in MWF correlated well with those of @entity0 in the air near the machines (correlation coefficient r=.69). The results showed that the @entity1 levels in MWF should continuously be kept high enough (>500 ppm) to prevent workers' exposure to endotoxins and bacteria. Overdosing with @entity1 , however, should be avoided, so that the levels of airborne @entity0 remain low. @entity1 levels in MWF can be followed by the method described in this article. Workers' exposure to contaminants of MWF can be reduced substantially by enclosing the machines and equipping them with local exhausts.

title: Control of workers' exposure to airborne endotoxins and XXXX during the use of metalworking fluids.

answer: @entity0


abstract: SUMMARY: Effectiveness of restricted and desired gains index selection to change growth and body composition was tested in @entity0 . Replicate lines were selected within full-sib families as follows: RI, restricted index to increase 12-week body weight (BW) and @entity1 ( @entity1 ) with no change in right epididymal fat pad weight (EF); DG, desired gains index to increase BW and @entity1 and decrease EF and right subcutaneous fat pad weight (SF) in designated proportions; RS, random selection. Realized heritabilities of index units, converted to an individual basis, were 0.65    0.17 in RI and 0.50    0.23 in DG, which exceeded the respective base population estimates of 0.32    0.11 and 0.37   0.11, calculated as twice the regression of son on sire. Realized genetic correlation between the two selection index units of 0.87    0.12 was not significantly different from the base population estimate of 0.91    0.21. Realized correlated responses in component traits of the indices did not agree closely with expectation. Possible explanations for these discrepancies include genetic drift, weak selection intensity, discrepancies between estimated and true genetic parameters and changes in genetic parameters due to selection. Antagonistic selection for multiple traits may magnify the importance of these factors. ZUSAMMENFASSUNG: Restringierte und erw  nschte genetische Fortschritte zur Ver  nderung von Wachstum und K  rperzusammensetzung von M  usen Die Wirksamkeit restraingierter und erw  nschter Fortschritt-Indexselektionsver  nderung von Wachstum und K  rpergewicht wurde bei M  usen gepr  ft. Wiederholungslinien wurden innerhalb Vollgeschwisterfamilien folgenderma  en selektiert: RI, restringierter Index zur Steigerung des 12-Wochengewichtes (BW), Schlachtk  rperh  lfte ( @entity1 ) ohne   nderung des rechten Nebenhodenfettgewichts (EF); TG, erw  nschter Zuchtfortschrittindex zur Steigerung von BW und @entity1 und Verminderung von EF des rechten subkutanen Fettanteils (SF) in erw  nschten Verh  ltnissen; RS Zufallsselektion. Realisierte Heritabilit  tswerte im Index, auf individuelle Basis umgerechnet, waren 0,65   0,17 bei RI und 0,50    0,23 bei DG, die die diesbez  glichen Basispopulationssch  tzungen von 0,23   0,11 und 0,37   0,11   bertrafen. Diese wurden als die doppelte Regression von Sohn auf Vatertier berechnet. Realisierte genetische Korrelationen zwischen den zwei Selektionsindexeinheiten von 0,87 unterschieden sich nicht signifikant vom Basispopulationswert 0,91    0,21. Realisierte korrelierte Selektion-sreaktionen in den Teilmerkmalen der Indices haben mit den Erwartungswerten nicht gut   bereingestimmt. M  gliche Erkl  rung f  r diese Abweichung beinhalten genetische Drift, schwache Selektionsintensit  t, Nicht  bereinstimmung zwischen gesch  tzten und wahren genetischen Parametern und Ver  nderungen in diesen durch Selektion. Antagonistische Selektion f  r mehrere Merkmale k  nnte die Bedeutung dieser Faktoren steigern.

title: Multitrait restricted and desired gains selection indices designed to change growth and body composition in XXXX (1).

answer: @entity0


abstract: SUMMARY: To identify the @entity1 chromosome carrying the genes coding for GAPD, @entity2 , and @entity3 , karyotypic examination was carried out on 14 buffalo-hamster hybrid clones previously tested for presence of this syntenic group. In @entity0 , this group (U3) has been assigned to chromosome 5, which is assumed to be homologous to the long arm of buffalo chromosome 4. Chromosome 4 was present in all five clones expressing the three enzymes, and absent in all seven negative clones, indicating that in the buffalo GAPD, @entity2 , and @entity3 are located on chromosome 4. One clone, expressing GAPD and @entity2 , but not @entity3 , was found to carry a translocation between hamster marker chromosome M(2) and buffalo 4q1  >  4qter. In another clone, expressing @entity3 , but not GAPD and @entity2 , chromosome 4 was absent, while a very small, unidentifiable acrocentric was present. These observations suggest that @entity3 is located in the proximal part of 4q1, and that GAPD and @entity2 are located more distally, in 4q1  >  4q2. ZUSAMMENFASSUNG: Lokalisierung von Genen auf Chromosom 4 des Flu  b  ffels durch B  ffel-Hamster-Hybridzellen Zur Identifikation von Flu  b  ffelchromosomen mit Genen f  r GAPD, @entity2 und @entity3 wurden Karyotypenbestimmungen an 14 B  ffel-Hamster-Hybridklonen durchgef  hrt, die vorher auf Anwesenheit der betreffenden synthenischen Gruppen gepr  ft worden waren. Bei Rindern wird diese Gruppe (U3) dem Chromosom 5 zugeordnet, welches als homolog mit dem langen Arm des B  ffelchromosoms 4 betrachtet wird. Chromosom 4 war in allen f  nf Klonen, die die drei Enzyme exprimiert haben, vorhanden und fehlte in allen sieben negativen klonen, so da   angenommen werden kann, da   sich bei B  ffeln GAPD, @entity2 und @entity3 auf Chromosom 4 befinden. Bei einem Klon, der GAPD und @entity2 , aber nicht @entity3 zeigte, wurde eine Translokation zwischen dem Hamstermarkerchromosom M2 und B  ffel 4q1  >  4qter gefunden. Im einem anderen Klon, der @entity3 , nicht aber GAPD und @entity2 zeigte, war Chromosom 4 nicht vorhanden, wohl aber ein sehr kleines, nicht identifizierbares akrozen-trisches Chromosom. Diese Beobachtungen weisen darauf hin, da   sich @entity3 im proximalen Teil von 4q1 befindet und GAPD und @entity2 vertu distal in 4q1  >  4q2 lokalisiert sind.

title: Assignment of genes to chromosome 4 of the XXXX with a panel of buffalo-hamster hybrid cells.

answer: @entity1


abstract: The mainstay of treatment for @entity2 , AF, remains pharmacologic control, either by maintaining sinus rhythm or by controlling the ventricular rate and allowing AF to continue. In @entity0 where pharmacologic therapy i not effective, not tolerated or contraindicated, nonpharmacologic treatment may be beneficial. In the last two decades the number of nonpharmacologic treatment options (catheter ablation, cardiac pacing, internal defibrillation, and @entity1 surgery) for AF have markedly increased and the number of @entity0 undergoing such treatment is steadily increasing. The most important reason for these treatment strategies is the hope of reducing symptoms, preventing complications and improving quality of life, QoL. However, the impact of nonpharmacologic therapy on QoL is far from established. Following a short presentation of the basic definitions and instruments used in QoL research the present paper reviews clinical studies that have assessed QoL in @entity0 undergoing nonpharmacologic treatment of AF. Major limitations and methodological problems are emphasized. Among these are highly selected often-heterogeneous @entity0 groups, small size, lack of control group and the use of non-validated QoL instruments. Furthermore, in most studies antiarrhythmic medication have been discontinued at the time of the intervention and it is not clear to which degree the improvement in QoL is related solely to the nonpharmacologic treatment or to the removal of drug related adverse effects. Although the currently available data from adequately designed studies are sparse and further investigations are needed, it is noteworthy that the majority of @entity0 undergoing nonpharmacologic treatment report enhanced QoL.

title: Quality of life in nonpharmacologic treatment of XXXX .

answer: @entity2


abstract: @entity1 proteases such as caspases play important roles in @entity0 ( @entity0 ) of metazoans. Plant metacaspases (MCPs), a family of @entity1 proteases structurally related to caspases, have been hypothesized to be ancestors of metazoan caspases, despite their different substrate specificity. @entity2 contains six type II MCP genes (AtMCP2a-f). Whether and how these individual members are involved in controlling @entity0 in plants remains largely unknown. Here we investigated the function and regulation of AtMCP2d, the predominant and constitutively expressed member of type II MCPs, in stress-inducible @entity0 . Two AtMCP2d mutants (mcp2d-1 and mcp2d-3) exhibited reduced sensitivity to @entity0 -inducing mycotoxin @entity4 as well as oxidative stress inducers, whereas AtMCP2d over-expressors were more sensitive to these agents, and exhibited accelerated cell-death progression. We found that AtMCP2d exclusively localizes to the cytosol, and its accumulation and self-processing patterns were age-dependent in leaves. Importantly, active proteolytic processing of AtMCP2d proteins dependent on its catalytic activity was observed in mature leaves during mycotoxin-induced cell death. We also found that mcp2d-1 leaves exhibited reduced cell death in response to @entity3 carrying avirulent gene avrRpt2, and that self-processing of AtMCP2d was also detected in wild-type leaves in response to this pathogen. Furthermore, increases in processed AtMCP2d proteins were found to correlate with conditional cell-death induction in two lesion-mimic mutants (cpr22 and ssi4) that exhibit spontaneous cell-death phenotypes. Taken together, our data strongly suggest that AtMCP2d plays a positive regulatory role in biotic and abiotic stress-induced @entity0 .

title: XXXX metacaspase 2d is a positive mediator of cell death induced during biotic and abiotic stresses.

answer: @entity2


abstract: BACKGROUND: @entity2 ( @entity2 ) is increasingly recognised in @entity0 presenting with features of @entity7 . We present a single centre experience of @entity2 with medium term follow up. METHODS: Fifty-two consecutive @entity0 presenting with a diagnosis of @entity2 were included. The clinical presentation, complications, baseline and follow-up echocardiograms and cardiac magnetic resonance imaging were analysed. RESULTS: Fifty-one @entity0 were female. A stressful event preceded presentation in 37 (71%) @entity0 . @entity3 was the most common symptom (83%). Two @entity0 presented with an out-of-hospital @entity6 . ST segment elevation (40%) and global T wave inversion (44%) were the most frequent electrocardiogram changes. Left ventricular assessment demonstrated typical apical ballooning in 41 @entity0 and 11 @entity0 demonstrated the mid-wall variant. In-hospital complications occurred in 11 @entity0 (21%) and included @entity1 (n = 2), @entity8 (n = 5); two of whom had a significant left ventricular outflow gradient, @entity4 (n = 1), @entity5 (n = 2) and a cerebrovascular event (n = 2). Left ventricular function at presentation and follow up was compared in 40 @entity0 . The mean ejection fraction in this group at presentation was 47% (20-70%) compared with that at follow up of 63% (44-76%). There were no significant complications or recurrences at follow up. CONCLUSIONS: While @entity2 is a reversible condition with low rates of complications and recurrence at follow up it is, as demonstrated in our cohort, associated with significant in-hospital morbidity in a proportion of @entity0 .

title: XXXX : an Australian single centre experience with medium term follow up.

answer: @entity2


abstract: BACKGROUND: Mixed @entity2 share both central and obstructive components and are often treated as if they are obstructive events. The hypothesis is that @entity0 with @entity1 ( @entity4 ) who exhibit a majority of mixed @entity2 will differ in ventilatory control from those with predominantly obstructive @entity2 during wakefulness; moreover, this difference could affect nasal continuous positive airway pressure (CPAP) adherence. METHODS: In a retrospectively derived case-control study, 5 min of respiratory inductance plethysmography signals during wakefulness prior to sleep onset were extracted from a diagnostic polysomnogram in these groups: (1) mixed @entity2 -dominant @entity4 (mix- @entity4 ) (n = 36), (2) obstructive @entity2 -dominant @entity4 ( @entity4 ) (n = 20), (3) central @entity3 (pure-CSAS) (n = 6), and (4) control subjects (n = 10). Breathing patterning was compared between the groups using the coefficient of variation (CV) for breath-to-breath inspiration time (TI), expiration time (TE), TI + TE (Ttot), and tidal volume, and an information theory-based metric of signal pattern variability (sample entropy). Subsequent CPAP adherence over 12 months was determined in @entity4 groups. RESULTS: Breath-to-breath CV parameters and sample entropy in the mix- @entity4 group were significantly greater as compared with the @entity4 and control groups. In a subanalysis, CV and sample entropy were similar in the mix- @entity4 and the pure-CSAS groups. CPAP adherence was significantly poorer in mix- @entity4 compared with @entity4 . CONCLUSIONS: During wakefulness, both breath patterning and sample entropy in mix- @entity4 are similar to pure-CSAS and more variable than in @entity4 . In addition, CPAP adherence was decreased in @entity0 with mix- @entity4 , which may be related to basic differences in respiratory control.

title: Differences in breathing patterning during wakefulness in @entity0 with mixed XXXX .

answer: @entity1


abstract: BACKGROUND: Mixed @entity2 share both central and obstructive components and are often treated as if they are obstructive events. The hypothesis is that @entity0 with @entity1 ( @entity4 ) who exhibit a majority of mixed @entity2 will differ in ventilatory control from those with predominantly obstructive @entity2 during wakefulness; moreover, this difference could affect nasal continuous positive airway pressure (CPAP) adherence. METHODS: In a retrospectively derived case-control study, 5 min of respiratory inductance plethysmography signals during wakefulness prior to sleep onset were extracted from a diagnostic polysomnogram in these groups: (1) mixed @entity2 -dominant @entity4 (mix- @entity4 ) (n = 36), (2) obstructive @entity2 -dominant @entity4 ( @entity4 ) (n = 20), (3) central @entity3 (pure-CSAS) (n = 6), and (4) control subjects (n = 10). Breathing patterning was compared between the groups using the coefficient of variation (CV) for breath-to-breath inspiration time (TI), expiration time (TE), TI + TE (Ttot), and tidal volume, and an information theory-based metric of signal pattern variability (sample entropy). Subsequent CPAP adherence over 12 months was determined in @entity4 groups. RESULTS: Breath-to-breath CV parameters and sample entropy in the mix- @entity4 group were significantly greater as compared with the @entity4 and control groups. In a subanalysis, CV and sample entropy were similar in the mix- @entity4 and the pure-CSAS groups. CPAP adherence was significantly poorer in mix- @entity4 compared with @entity4 . CONCLUSIONS: During wakefulness, both breath patterning and sample entropy in mix- @entity4 are similar to pure-CSAS and more variable than in @entity4 . In addition, CPAP adherence was decreased in @entity0 with mix- @entity4 , which may be related to basic differences in respiratory control.

title: Differences in breathing patterning during wakefulness in XXXX with mixed @entity1 .

answer: @entity0


abstract: BACKGROUND AND PURPOSE: Intracranial @entity4 is especially prevalent in Asians, but intracranial stent placement and medical treatment for severe @entity6 are controversial. Thus, we compared long-term outcomes of these 2 therapeutic approaches in an Asian population. MATERIALS AND METHODS: @entity0 with angiographically proved severe (>= 70%) symptomatic @entity8 , with or without stent placement, were retrospectively reviewed at a single center between 2002 and 2009, with adjustments for age, sex, vascular risk factors, degree of baseline @entity5 , and baseline functional status. RESULTS: Of the 114 @entity0 followed from 3 to 36 months (mean, 17.3 months) after initial diagnosis, 53 received 56 stents in addition to medical treatment (stent-placement group), and 61 matched @entity0 received only medical treatment (medical group). Total clinical events, including @entity2 , @entity9 , and @entity3 , were 12 (22.6%) and 15 (24.6%) in the stent-placement and medical groups, respectively (P = .99). The stent-placement group had significantly better functional outcomes than the medical group (94.3% versus 78.7% for mRS scores of 0-3, P = .045). Most events in the stent-placement group occurred within the first week of the periprocedural period (17.0%) as minor embolic or perforator @entity7 , and the rate of events decreased thereafter (5.7%, P = .07). Stent placement over the perforator-rich MCA and BA independently predicted periprocedural events on multivariate regression analysis. In the medical group, events increased in frequency (21.7%) and severity with time. CONCLUSIONS: Although the total @entity1 event rate was similar in the 2 groups during a 3-year follow-up, the stent-placement group had a more favorable functional outcome despite minor periprocedural @entity2 .

title: Stenting versus medical treatment for severe symptomatic XXXX .

answer: @entity6


abstract: @entity6 Don cells in log-phase were exposed to Colcemid during the G2 period with and without a combination of divalent cation chelators and mitochondrial inhibitors. Isolated metaphase cells were incubated as follows: (i) without Colcemid but with other agents and the progression was monitored from metaphase (M) to telophase (Tel) and to cell division; (ii) with @entity9 and other agents and the rate of micronuclei formation in the absence of anaphase was studied. Both @entity2 and @entity7 accelerated the progression from M to Tel, but did not affect the overall rate of cell division. @entity3 (CAP), an inhibitor of mitochondrial protein synthesis, blocked the effect of the chelators and also retarded the progression. An inhibitor of mitochondrial respiration, @entity8 (AA), also retarded the progression in the absence of the chelators and prevented the promoting effect of the chelators. A stimulator of ATPase for @entity1 breakdown. @entity4 ( @entity5 ), accelerated the M to Tel progression. @entity3 (CAP) and AA, as well as @entity5 , appeared to have little effect on the formation of micronuclei in the presence of Colcemid. @entity7 , which affects cell surface @entity0 , stimulated the formation of micronuclei. This study indicates that @entity0 ions and mitochondrial function are involved in the regulation of a certain segment of mitosis beyond metaphase, with @entity0 sequestration in the mitochondria and chelation of @entity0 by @entity7 as dominant factors.

title: Effect of mitochondrial inhibitors on metaphase-telophase progression and nuclear membrane formation in XXXX cells.

answer: @entity6


abstract: Twenty-six, ten-week-old mink were infected by force feeding by pipette 2 ml of a tissue suspension containing a Wisconsin strain of @entity4 . Four days later, @entity1 and partial or complete loss of appetite developed simultaneously in all of the animals. @entity2 were also observed. By the sixth day after inoculation, all of the mink were anorectic and weak. @entity3 persisted for 48 to 96 hours. @entity1 and @entity2 continued until the eighth to ninth day after exposure. For the first two days after the appearance of @entity1 , the feces contained large quantities of mucus and intestinal casts were seen frequently in the droppings. Thereafter, the feces consisted mostly of yellowish green, watery fluid and contained no casts. Some of the animals died on the eighth day after @entity0 . Those which survived were severely dehydrated and debilitated, but resumed eating and achieved complete clinical recovery within the next five to six days. @entity5 , i.e., total leukocyte count of less than 5,000 cells per mm(3) of blood, was found in seven of nine mink examined during the height of the disease. Leukopenic animals were @entity6 and neutrophils.

title: Some clinical and hematological features of XXXX of mink.

answer: @entity4


abstract: OBJECTIVE: To investigate the relationship between dynamic change of electrogastrogram (EGG) with @entity3 of antrum during migrating motor complex (MMC) cycle in @entity1 and @entity4 , and to verify whether a 100% coupling of electrical and mechanical events existed after meal. METHODS: Eleven @entity1 ( @entity1 ) and 14 @entity0 with @entity4 ( @entity4 ) were studied. An 8-channel Dent-sleeve catheter was positioned under fluoroscopic guidance across antropyloroduodenal region and bipolar electrodes were attached to the skin corresponding to the location of antrum. Antropyloroduodenal pressure waves and electrical signals were transferred simultaneously to PC Polygraph ( @entity5 ) and recorded for 3 hours preprandially and 2 hours after ingestion of 40 g solid meal (336 kJ). The power of EGG and @entity3 ( @entity3 ) of antral contractions were calculated as the area under curve (AUC) by a build-in computer program. RESULTS: The power increases of EGG increased significantly in phase II (P < 0.01), phase III (P < 0.01) and after meal (P < 0.01) compared with phase I in @entity1 , however, this dynamic increase was not found in @entity4 . The power of EGG was positively correlated with the @entity3 of antrum both in @entity1 (r = 0.87, P < 0.01) and in @entity4 (r = 0.79, P < 0.01) during the interdigestive period. A significant increase of EGG power after meal was found in @entity1 , which corresponded to the degree of phase III and kept stable for the whole postprandial period. In contrast, power increase was not found in @entity4 except during 30 min after test meal. CONCLUSIONS: Prolonged cutaneous EGG recording can reflect the periodic variation of @entity2 cycle. EGG response in @entity1 but not in @entity4 after meal is characterized as persistent increase which is corresponded to phase III.

title: [Electrogastograph during interdigestive and digestive stages in @entity0 with XXXX ].

answer: @entity4


abstract: OBJECTIVE: To investigate the relationship between dynamic change of electrogastrogram (EGG) with @entity3 of antrum during migrating motor complex (MMC) cycle in @entity1 and @entity4 , and to verify whether a 100% coupling of electrical and mechanical events existed after meal. METHODS: Eleven @entity1 ( @entity1 ) and 14 @entity0 with @entity4 ( @entity4 ) were studied. An 8-channel Dent-sleeve catheter was positioned under fluoroscopic guidance across antropyloroduodenal region and bipolar electrodes were attached to the skin corresponding to the location of antrum. Antropyloroduodenal pressure waves and electrical signals were transferred simultaneously to PC Polygraph ( @entity5 ) and recorded for 3 hours preprandially and 2 hours after ingestion of 40 g solid meal (336 kJ). The power of EGG and @entity3 ( @entity3 ) of antral contractions were calculated as the area under curve (AUC) by a build-in computer program. RESULTS: The power increases of EGG increased significantly in phase II (P < 0.01), phase III (P < 0.01) and after meal (P < 0.01) compared with phase I in @entity1 , however, this dynamic increase was not found in @entity4 . The power of EGG was positively correlated with the @entity3 of antrum both in @entity1 (r = 0.87, P < 0.01) and in @entity4 (r = 0.79, P < 0.01) during the interdigestive period. A significant increase of EGG power after meal was found in @entity1 , which corresponded to the degree of phase III and kept stable for the whole postprandial period. In contrast, power increase was not found in @entity4 except during 30 min after test meal. CONCLUSIONS: Prolonged cutaneous EGG recording can reflect the periodic variation of @entity2 cycle. EGG response in @entity1 but not in @entity4 after meal is characterized as persistent increase which is corresponded to phase III.

title: [Electrogastograph during interdigestive and digestive stages in XXXX with @entity4 ].

answer: @entity0


abstract: Poor efficacy is one of the issues for clinical islet transplantation. Recently, we demonstrated that pancreatic ductal preservation significantly improved the success rate of islet isolation; however, two transplants were necessary to achieve insulin independence. In this study, we introduced @entity8 -based purification, thymoglobulin induction, and double blockage of @entity5 and @entity3 as well as @entity6 -free immunosuppression to improve the efficacy of clinical islet transplantation. Nine clinical-grade @entity0 pancreata were procured. Pancreatic ductal preservation was performed using ET-Kyoto solution in all cases. When the isolated islets met the clinical criteria, they were transplanted. We utilized two methods of immunosuppression and anti- @entity2 . The first protocol prescribed daclizumab for induction, then @entity6 and @entity4 to maintain immunosuppression. The second protocol used thymoglobulin for induction and @entity4 and @entity7 mofetil to maintain immunosuppression. Eternacept and anakinra were administered as anti-inflammatory drugs. The total amount of insulin required, HbA1c, and the SUITO index were determined to analyze and compare the results of transplantation. All isolated islet preparations (9/9) met the criteria for clinical transplantation, and they were transplanted into six type 1 @entity1 @entity0 . All @entity0 achieved insulin independence with normal HbA1c levels; however, the first protocol required two islet infusions (N = 3) and the second protocol only required a single infusion (N = 3). The average SUITO index, at 1 month after a single-donor islet transplantation, was significantly higher in the second protocol (49.6    8.3 vs. 19.3    6.3, p < 0.05). Pancreatic ductal preservation, @entity8 -based purification combined with thymoglobulin induction, and blockage of @entity5 and @entity3 as well as @entity6 -free immunosuppression dramatically improved the efficacy of clinical islet transplantations. This protocol enabled us to perform successful single-donor islet transplantations. Further large-scale studies are necessary to confirm these results and clarify the mechanism of each component.

title: Improving efficacy of clinical islet transplantation with XXXX -based islet purification, thymoglobulin induction, and blockage of @entity5 and @entity3 .

answer: @entity8


abstract: Poor efficacy is one of the issues for clinical islet transplantation. Recently, we demonstrated that pancreatic ductal preservation significantly improved the success rate of islet isolation; however, two transplants were necessary to achieve insulin independence. In this study, we introduced @entity8 -based purification, thymoglobulin induction, and double blockage of @entity5 and @entity3 as well as @entity6 -free immunosuppression to improve the efficacy of clinical islet transplantation. Nine clinical-grade @entity0 pancreata were procured. Pancreatic ductal preservation was performed using ET-Kyoto solution in all cases. When the isolated islets met the clinical criteria, they were transplanted. We utilized two methods of immunosuppression and anti- @entity2 . The first protocol prescribed daclizumab for induction, then @entity6 and @entity4 to maintain immunosuppression. The second protocol used thymoglobulin for induction and @entity4 and @entity7 mofetil to maintain immunosuppression. Eternacept and anakinra were administered as anti-inflammatory drugs. The total amount of insulin required, HbA1c, and the SUITO index were determined to analyze and compare the results of transplantation. All isolated islet preparations (9/9) met the criteria for clinical transplantation, and they were transplanted into six type 1 @entity1 @entity0 . All @entity0 achieved insulin independence with normal HbA1c levels; however, the first protocol required two islet infusions (N = 3) and the second protocol only required a single infusion (N = 3). The average SUITO index, at 1 month after a single-donor islet transplantation, was significantly higher in the second protocol (49.6    8.3 vs. 19.3    6.3, p < 0.05). Pancreatic ductal preservation, @entity8 -based purification combined with thymoglobulin induction, and blockage of @entity5 and @entity3 as well as @entity6 -free immunosuppression dramatically improved the efficacy of clinical islet transplantations. This protocol enabled us to perform successful single-donor islet transplantations. Further large-scale studies are necessary to confirm these results and clarify the mechanism of each component.

title: Improving efficacy of clinical islet transplantation with @entity8 -based islet purification, thymoglobulin induction, and blockage of XXXX and @entity3 .

answer: @entity5


abstract: Poor efficacy is one of the issues for clinical islet transplantation. Recently, we demonstrated that pancreatic ductal preservation significantly improved the success rate of islet isolation; however, two transplants were necessary to achieve insulin independence. In this study, we introduced @entity8 -based purification, thymoglobulin induction, and double blockage of @entity5 and @entity3 as well as @entity6 -free immunosuppression to improve the efficacy of clinical islet transplantation. Nine clinical-grade @entity0 pancreata were procured. Pancreatic ductal preservation was performed using ET-Kyoto solution in all cases. When the isolated islets met the clinical criteria, they were transplanted. We utilized two methods of immunosuppression and anti- @entity2 . The first protocol prescribed daclizumab for induction, then @entity6 and @entity4 to maintain immunosuppression. The second protocol used thymoglobulin for induction and @entity4 and @entity7 mofetil to maintain immunosuppression. Eternacept and anakinra were administered as anti-inflammatory drugs. The total amount of insulin required, HbA1c, and the SUITO index were determined to analyze and compare the results of transplantation. All isolated islet preparations (9/9) met the criteria for clinical transplantation, and they were transplanted into six type 1 @entity1 @entity0 . All @entity0 achieved insulin independence with normal HbA1c levels; however, the first protocol required two islet infusions (N = 3) and the second protocol only required a single infusion (N = 3). The average SUITO index, at 1 month after a single-donor islet transplantation, was significantly higher in the second protocol (49.6    8.3 vs. 19.3    6.3, p < 0.05). Pancreatic ductal preservation, @entity8 -based purification combined with thymoglobulin induction, and blockage of @entity5 and @entity3 as well as @entity6 -free immunosuppression dramatically improved the efficacy of clinical islet transplantations. This protocol enabled us to perform successful single-donor islet transplantations. Further large-scale studies are necessary to confirm these results and clarify the mechanism of each component.

title: Improving efficacy of clinical islet transplantation with @entity8 -based islet purification, thymoglobulin induction, and blockage of @entity5 and XXXX .

answer: @entity3


abstract: The consumption of @entity7 during @entity4 synthesis and transmethylation reactions yields stoichiometric amounts of @entity8 and @entity9 , respectively. Information concerning the regulation of the two routes of @entity7 metabolism in viable cells under changing growth conditions is limited. The present experiments have measured the time-dependent accumulation of @entity8 and @entity5 in the medium of four malignant @entity0 and @entity1 cell lines deficient in @entity8 phosphorylase ( @entity8 : @entity6 methylthioribosyltransferase). Included in this group were anchorage-independent and anchorage-dependent cells. The enzyme-deficient cells did not detectably cleave @entity8 , and did not appreciably metabolize @entity3 . A comparison of @entity8 and @entity3 excretion therefore provided a noninvasive method for estimating the relative rates of @entity4 synthesis and transmethylation. Early after the release of @entity0 CEM lymphoblasts from density dependent @entity2 , @entity8 production increased, and exceeded @entity3 synthesis. @entity8 formation reached a maximum of 0.9 nmol/12 h per 10(6) cells prior to the onset of exponential growth. The kinetics of @entity3 synthesis were different. @entity3 accumulation was proportional to the specific growth rate, and achieved a peak of 3.1 nmol/12 h per 10(6) cells during mid-exponential phase, at which time @entity8 production was falling. Similar patterns of @entity8 and @entity3 excretion were observed in other @entity8 phosphorylase deficient cell lines. These data show that @entity4 synthesis and transmethylation are differentially regulated during the growth cycle of @entity0 cells.

title: Differential regulation of XXXX synthesis and transmethylation reactions in methylthioadenosine phosphorylase deficient @entity0 cells.

answer: @entity4


abstract: The consumption of @entity7 during @entity4 synthesis and transmethylation reactions yields stoichiometric amounts of @entity8 and @entity9 , respectively. Information concerning the regulation of the two routes of @entity7 metabolism in viable cells under changing growth conditions is limited. The present experiments have measured the time-dependent accumulation of @entity8 and @entity5 in the medium of four malignant @entity0 and @entity1 cell lines deficient in @entity8 phosphorylase ( @entity8 : @entity6 methylthioribosyltransferase). Included in this group were anchorage-independent and anchorage-dependent cells. The enzyme-deficient cells did not detectably cleave @entity8 , and did not appreciably metabolize @entity3 . A comparison of @entity8 and @entity3 excretion therefore provided a noninvasive method for estimating the relative rates of @entity4 synthesis and transmethylation. Early after the release of @entity0 CEM lymphoblasts from density dependent @entity2 , @entity8 production increased, and exceeded @entity3 synthesis. @entity8 formation reached a maximum of 0.9 nmol/12 h per 10(6) cells prior to the onset of exponential growth. The kinetics of @entity3 synthesis were different. @entity3 accumulation was proportional to the specific growth rate, and achieved a peak of 3.1 nmol/12 h per 10(6) cells during mid-exponential phase, at which time @entity8 production was falling. Similar patterns of @entity8 and @entity3 excretion were observed in other @entity8 phosphorylase deficient cell lines. These data show that @entity4 synthesis and transmethylation are differentially regulated during the growth cycle of @entity0 cells.

title: Differential regulation of @entity4 synthesis and transmethylation reactions in methylthioadenosine phosphorylase deficient XXXX cells.

answer: @entity0


abstract: @entity2 are the most common @entity1 . Surgical treatment can be difficult as a result of the high risk of @entity5 . The present study reviewed clinical features of @entity0 with @entity2 and surgical techniques used in their treatment. Eight @entity0 with @entity2 underwent hepatectomies at the Asan Medial Center between January 2006 and March 2009. @entity0 demographic, clinical, and surgical characteristics and outcomes were reviewed retrospectively. Seven females and one male @entity0 underwent hepatectomies during the study period. The median age was 48.5 years (range, 33 to 58 years). Indications for surgical interventions were @entity4 (62.5%), an abdominal mass (37.5%), @entity7 (25%), and increased @entity6 size (25%). The @entity6 were usually multiple (87.5%) and bilobar (75%) and had a median size of 14.5 cm (range, 7 to 29 cm). All @entity0 underwent major hepatic resection with early vascular control using the Glissonean pedicle transection method (GPTM), the @entity3 maneuver (LHM), and preparation for total vascular exclusion (TVE). There was no major morbidity or mortality. The minor morbidity rate was 25 per cent with transfusion rate of 37.5 per cent. Early vascular control using the GPTM, the LHM, and preparation for TVE is essential for safe resection of large @entity2 .

title: Surgical treatment of XXXX : technical point of view.

answer: @entity2


abstract: The clarification of turbid AA-amyloid-fibril-containing agarose gels by serum has been ascribed to degradation of the fibrils and designated as 'amyloid degrading factor'. In the present study, sera of 32 healthy blood donors and 32 @entity0 with @entity2 all showed 'degrading factor activity' against both @entity8 fibrils and a non-fibrillar reticulin preparation of normal liver in an agarose plate assay. @entity5 fibrils were not affected. The 'degrading activity' of serum was correlated with the serum @entity7 concentration, and the effect was also given by purified @entity0 and bovine serum @entity7 , although it was not seen with other serum proteins. The 'degrading activity' of serum against @entity8 and reticulin was significantly correlated: both substrates showed low levels in a @entity1 such as @entity2 , and reticulin inhibited 'degrading activity' against @entity8 . These results suggest the same process involves both substrates. 'Degrading activity' was also given by @entity4 and a specific @entity3 chelator, and was inhibited by @entity3 and @entity6 . An enzyme inhibitor showed only partial inhibition of the 'degrading activity' of serum, purified @entity7 , and @entity4 . These results suggest that serum 'degrading factor activity' is a non-specific @entity3 -mediated effect against @entity8 and reticulin preparations dispersed in agarose. It may represent a change in the degree of aggregation of these proteins rather than being an effect of proteolytic degradation. This confirms the conclusions of other workers that amyloid 'degrading factor activity' is an phenomenon in vitro of doubtful pathophysiological significance.

title: Amyloid 'degrading factor activity': a non-specific XXXX -mediated effect.

answer: @entity3


abstract: OBJECTIVE: Report the results of interventional or semi-interventional techniques for 173 @entity0 with @entity7 . METHOD: This group included 120 males and 53 females. The pathologic lesions composed of localized complete occlusion of inferior vena cava (IVC) (78), IVC @entity5 (49), IVC membrane with a hole (37), membrane of hepatic vein (HV) (3), IVC @entity3 (4), IVC membrane with @entity3 (2) and @entity1 with occlusion of HV (32). Treatment methods included that I: Percutaneous transinferior vena cava angioplasty (PTA) (76); II: IVC PTA with stent (59); III: Percutaneous transhepatic vein recanalization (3); IV: IVC thrombolysis through a catheter (4), V: Combined transcardiac and transfemoral venous membranotomy and @entity2 (22); VI: V and stent (17); VII: Stenting during radical surgery (3); @entity4 : Additional operation after intervention (23). RESULTS: The immediate technique success rate for intervention was 90.1%, for the semi-intervention was 100%. The IVC pressure was reduced from 3 to 29 cm @entity6 . Complications occurred in 8 cases. The death rate was 2.9%. A follow-up study showed the recurrence rates were 14.5% in IVC PTA group, 1.7% in IVC PTA with stent, 18.2% in combined technique without stent and no recurrence was found in other groups. CONCLUSION: The PTA is the first choice for localized lesions. When elastic recoil occurs, immediate stenting is suggested. The semi-interventional approach is advised for PTA failure and more complicated cases. For those with both @entity1 and occlusion of HV, the additional operation is needed after IVC intervention.

title: Interventional or semi-interventional treatment for XXXX .

answer: @entity7